Longeveron (LGVN) EPS (Diluted) Growth (1y) (2022 - 2026)
Longeveron (LGVN) EPS (Diluted) Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | 36.94% |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 468.98 Bn | 464.19 Bn | 1.35 Bn | 17,091.12% |
| 5 | Vertex Pharmaceuticals | 123.24 Bn | 115.99 Bn | 2.59 Bn | 61.58% |
| 6 | Regeneron Pharmaceuticals | 70.45 Bn | 61.70 Bn | 3.31 Bn | -7.16% |
| 7 | Belite Bio | 63.04 Bn | 63.04 Bn | - | - |
| 8 | Argenx Se | 55.79 Bn | 50.60 Bn | 1.41 Bn | 96.09% |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn | 1,158.84% |
| 10 | Longeveron | 15.11 Bn | 15.10 Bn | 264,000.00 | 48.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.51% |
| Dec 31, 2025 | 28.57% |
| Sep 30, 2025 | -17.25% |
| Jun 30, 2025 | 99.98% |
| Mar 31, 2025 | 99.97% |
| Dec 31, 2024 | 99.98% |
| Sep 30, 2024 | 99.99% |
| Jun 30, 2024 | 31.42% |
| Mar 31, 2024 | 91.55% |
| Dec 31, 2023 | -30.48% |
| Sep 30, 2023 | -11.64% |
| Jun 30, 2023 | -13.53% |
| Mar 31, 2023 | -936.80% |
| Dec 31, 2022 | -108.95% |
| Sep 30, 2022 | 79.16% |
| Jun 30, 2022 | 77.73% |